Educational evidence summaries. No dosing, sourcing, or treatment instructions.
Safety signals and evidence gaps involving the GH and IGF-1 axis.
An evidence-led CJC-1295 and Ipamorelin Combination review focused on adverse-event reporting, human-study limits, regulatory context and claim verification.
Reviewed by Clinical Trial Review TeamAn evidence-led CJC-1295 and Ipamorelin Combination review focused on immunogenicity questions, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led CJC-1295 and Ipamorelin Combination review focused on safety signal review, human-study limits, regulatory context and claim verification.
Reviewed by Regulatory Review DeskAn evidence-based review of reactions reported in human research and FDA concerns involving compounded CJC-1295.
Reviewed by Clinical Trial Review TeamAn evidence-led GHRH Analogues review focused on adverse-event reporting, human-study limits, regulatory context and claim verification.
Reviewed by Clinical Trial Review TeamA source-led review of human ipamorelin research, separating acute growth-hormone measurements from unproven clinical outcomes.
Reviewed by Clinical Trial Review TeamA regulatory history of sermorelin, including former Geref products, discontinuation and the status of compounded preparations.
Reviewed by CJC Axis Editorial TeamAn evidence-led GHRH Analogues review focused on immunogenicity questions, human-study limits, regulatory context and claim verification.
Reviewed by Regulatory Review DeskAn evidence-led GHRH Analogues review focused on safety signal review, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence Desk